Densitas’ Machine Learning Software for Breast Health Available On EnvoyAI Platform

See original article here DM-Density personalized breast density reporting software will be offered via vendor neutral artificial intelligence distribution platform Chicago, IL – November 26, 2017 – Advanced breast imaging analytics provider, Densitas, today announced that it now offers its automated breast density software through EnvoyAI’s scalable distribution platform to facilitate streamlined deployment of its flagship product within hospital networks and clinics. The software, DM-Density, helps radiologists provide tailored, patient-specific follow-up care. “We’re pleased to offer hospitals and physicians the opportunity to use Densitas’ breast density software either on-premise or in the cloud. We’re committed to providing our customer base with secure access to innovative AI products globally,” said Misha Herscu, CEO, EnvoyAI. “Densitas’ breast density software is a welcome addition to the many clinically useful applications available on the EnvoyAI Exchange.” “We’re pleased to partner with EnvoyAI to streamline deployment of our automated breast density software to empower health systems to standardize high quality care for women and improve workflow,” said Mohamed Abdolell, CEO, Densitas. “The EnvoyAI platform provides a unique opportunity to rapidly expand our footprint so these important outcomes can be achieved.” DM-Density is a machine learning application that provides on demand automated breast density assessments at point-of-care. The software analyzes standard digital mammograms and integrates seamlessly with PACS systems. The reports provide radiologists with insights to make better follow-up care decisions consistently and confidently. About Densitas Densitas develops machine learning technologies that deliver actionable information for personalized breast health. The technologies address the key challenges facing breast screening, including mammography quality, workflow, compliance and costs, with the aim of improving patient health efficiently and effectively. Densitas has received regulatory clearance to sell its automated breast density assessment software in Canada and the European Union. Learn more. About EnvoyAI  EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end users. EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer ­­­intellectual property. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians. www.envoyai.com   Media Contact:Alex MorrisDirector, Programs and Regulatory Affairs Densitas alex@densitas.health 647-470-4363]]>

ENTREVESTOR: PhotoDynamic Set for Clinical Trials

See original Entrevestor Article here By Peter Moreira Halifax-based PhotoDynamic Inc. will put its plaque-killing oral health product through clinical trials in the next month, the outcome of which will shape its strategy for the next few years. The company will test its product with 20 patients at the Forsyth Institute in Boston, one of the world’s most prestigious research facilities in the field of oral health. If it gets good results from these tests, the company plans to work closely with a Fortune 100 consumer products company to bring the product to market. That product — called PD Foam and PD Tray — is a system that kills plaque buildup on teeth through a combination of light and an extract from a plant that grows wild in Nova Scotia. Because the plant is known to be safe for human consumption, the product has a relatively simple regulatory path. Its initial target market is the one-fifth of the population who suffer from excessive plaque buildup on their teeth regardless of how much they brush. “We’ll start in a few weeks and have the results by January,” said CEO Martin Greenwood in an interview. “If the results are good, it will be easy to raise our next round (of financing) and then we’ll be moving on to a larger trial.” In the spring of 2016, PhotoDynamic raised $250,000 in equity funding through the First Angel Network, and supplemented that capital with money from government programs. The company, which grew out of research by Acadia University professor Sherri McFarland, has remained lean with four employees and used the FAN money to build a working prototype. PhotoDynamic has developed foam made from the plant extract, which the user places in the top and bottom trays of a special mouthpiece, like a mouthguard a hockey player would wear and which contains LED lights. Users turn on the lights, place the device in their mouth for one minute, and the plaque is gone. So far the system has killed plaque successfully in a petri dish and in animal tests, but surprises can crop up in human trials, Greenwood said. For example, 10 subjects will be given the PhotoDynamic device and the other 10 a placebo, to establish a clear gap between plaque buildup in the two groups. If a few of the 10 placebo-takers obsessively brush their teeth all day, it could skew the results. Greenwood feels confident in the PD Foam and Tray and believes the company has positioned itself to proceed promptly with its commercialization. It has built up a strong working relationship with its multinational partner (whom Greenwood declines to name publicly), and that could help bring the product to market. PhotoDynamic has also strengthened its board, recently adding former Johnson & Johnson consumer products CTO Neal Matheson and Barry Turner, a former vice-president of global complimentary medicines with Warner-Lambert. Assuming the trials are successful, Greenwood plans to raise about $1.5 million to take the company through the next two years. In that period he hopes to fine-tune the engineering of the product and carry out more thorough clinical trials, involving about 75-125 people over six months. Then Greenwood plans to sell the oral health product to a large company that can develop it, and PhotoDynamic will use the proceeds to work on other applications for the plant extract. “The way to really grow this company is to say, ‘We’re the people that can really take this technology to its potential,’” he said. “Let us be the R&D hub. . . . What we want to do is hit a home run and take the funds and reinvest them into the next one.”]]>

ENTREVESTOR: TruLeaf To Use Data, AI in Farming

See original Entrevestor article here By Peter Moreira With its indoor farm in Guelph, Ont., nearing completion, TruLeaf Sustainable Agriculture is plotting its next phase of growth with more farms, a licensing model for its technology and a new round of funding. Gregg Curwin, founder and CEO of the Halifax vertical farming company, also says the company is focused ever more on machine learning and data analytics to help it produce the most nutritious local food possible. Halifax-based TruLeaf aims to be a leader in sustainable agriculture through the use of vertical farming — which combines proven hydroponic technology with advancements in LED lighting and reclaimed rainwater to allow year-round production of plants indoors. Vertical farming is nearly 30 times more efficient than traditional agriculture, uses as much as 95 per cent less water, and takes up less land. Curwin told a panel discussion at the Big Data Congress last week that the company is now focusing on applying advanced technology to the process of growing plants indoors. The Guelph plant — which is due to be completed in June, will be fully automated and TruLeaf is looking into using data to improve the process of growing nutritious food. “The light bulb that’s going off for us is all about machine learning and data,” said Curwin. Curwin said that in the controlled environment of its growing facilities, the company can monitor data produced over time from the creation of the seed to shipping grown food to the supermarket. Outdoors, a farmer can get 40 points of data in his or her career; TruLeaf can get 10,000 data points in 10 days at its indoor farms. One example of TruLeaf’s experimentation is the work it has been doing with LED lighting. The company is experimenting with how different plants grow under different light spectrums, and what lighting is best at specific phases of the growing process. It is even examining whether special lighting in a supermarket shelf can prolong the freshness of produce. Curwin added that the company is investigating whether there is a direct link between adding certain greens to your diet and improving cognitive health. It is interested in producing in Nova Scotia a vegetable prominent in West Africa, where dementia rates are really low. “Can we make a defensible claim about the prevention of cognitive diseases?” he asked. “Making accurate claims is a significant goal of ours.” The last 18 months have been busy ones for TruLeaf. It closed an $8.5-million financing round last December and has been working with Loblaw Companies, the parent company of Atlantic Superstores, on the development of its farms. Appearing under the company’s GoodLeaf Farms brand, products grown in the company’s farm in Bible Hill are now available in a dozen Superstores spanning the three Maritime provinces. According to the TruLeaf website, the products include broccoli shoots, kale shoots, daikon radish shoots, pea shoots, baby arugula and baby kale. The company now has 38 employees in Nova Scotia. “We’re eliminating low-level jobs and most of the jobs we are creating now are . . . in computer science, engineering and plant science,” said Curwin.]]>

Appili Therapeutics Receives $1.2M USD from the Department of Defense to Advance Antibiotic Targeting Drug-Resistant Bacteria

See original post here For Immediate Release November 7, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, announced today it has been awarded a $1.2 million USD grant by the Department of Defense, Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program . The Peer Reviewed Medical Research Program (PRMP) supports military health-related research that has the potential to make a strong impact on patient care. Appili will use the funds to develop a lead compound as a preclinical candidate for its ATI-1503 antibiotic program targeting drug-resistant, Gram-negative bacteria. “Drug-resistant bacteria threaten a doctor’s ability to care for battlefield wounds among military service men and women,” said Kevin Sullivan, CEO of Appili Therapeutics. “We are honoured to have been selected for this PRMRP award, which helps us advance our most promising antibiotic candidate through the critical early stages of development.” Drug-resistant bacteria constitute some of the highest threats to human health, with over 2 million infections and at least 23,000 deaths each year in the U.S. alone. These superbugs can present serious challenges in both battlefield situations, as well as in veterans’ hospitals, making it a priority research area for the Department of Defense (DOD). ATI-1503 is a synthetic version of the naturally-occurring antibiotic called Negamycin.  Its broad spectrum activity allows it to tackle the most deadly Gram-negative bacteria, including Klebsiella pneumoniae, Acinetobactor baumannii, and Pseudomonas aeruginosa.  These are high priority pathogens for the Centers for Disease Control and Prevention and the World Health Organization because of the lack of effective antibiotic treatment options for the most resistant strains. Appili’s expert drug development team will use the PRMRP funding to optimize the potency of ATI-1503 to effectively target Gram-negative bacteria. Because Gram-negative bacteria have two protective cellular walls, it is hard for existing antibiotics to penetrate.  ATI-1503 holds promise for treating these superbugs because it penetrates the double exterior membranes and attacks the protein generating machinery of the Gram-negative bacteria.   About the PRMRP Grant This work is supported by the DOD Congressionally Directed Medical Research Programs through the Peer Reviewed Medical Research Program under Award No. W81XWH-17-1-0180. In conducting this research, the investigators will adhere to the laws of the United States and regulations of the Department of Agriculture, as well as the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories. For more information, visit http://cdmrp.army.mil.   About Appili Therapeutics Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including C. difficile. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat drug-resistant Gram-negative infections. For more information visit www.AppiliTherapeutics.com. Media Relations Contact: Jennifer Cameron T: 902-209-4704 E: Media@AppiliTherapeutics.com Investor Relations Contact: Kevin Sullivan, CEO, Appili Therapeutics T: 902-442-4655 E: Info@AppiliTherapeutics.com]]>

CKBW: Electric Puppets pairs with IWK Eye Care Clinic

Read the original article here Virtual Reality is coming to Nova Scotian Health Care. Ryan Cameron and his Electric Puppets won $50,000 from the Spark Innovation Challenge. He paired with the IWK Eye Care Clinic to improve their diagnostic and therapeutic tools. He says it will let them track patient’s eye movements and pupil dilation. “That gives us all kinds of diagnistic data about conditions and things they have in their eyes, including things like alignment,” he said. “In some ways an unprecedented amount of data compared to the current tools they have.” Other sparks winner from the South Shore include Finleaf Technologies, Nexus Robotics and Suru. Spark funds technology-based businesses in early stages of development. They first launched in Cape Breton in 2014 and have expanded across the province.]]>